



Vaccines



For more than 70 years, we have supplied routine vaccines to help protect the health of people in Japan including measles, rubella and mumps. Today, we're expanding our global vaccine business by relying on innovation to tackle some of the world's most challenging infectious diseases, such as dengue, COVID-19 and pandemic influenza.

Our team brings an outstanding track record and a wealth of knowledge in global vaccine development and manufacturing to advance a pipeline of vaccines to address some of the most pressing public health needs.

Our mission is to develop and deliver innovative vaccines that tackle some of the toughest problems in public health and improve the lives of people around the world.

The Value of Vaccination

- Vaccines prevent 3.5 to 5 million deaths each year and have transformed global public health.¹
- Vaccines are one of the most cost-effective ways to save lives.²
- 50 million deaths can be prevented through immunization between 2021 and 2030.³

Disease Areas

Dengue

- A mosquito-borne viral disease that continues to spread around the world.⁴
- Estimated that half of the world's population is at risk of dengue infection.⁴

COVID-19

- Caused by a new coronavirus, SARS-CoV-2, first identified in December of 2019.^{5,6}
- COVID-19 cases have been identified worldwide.⁶

Pandemic Influenza

- Influenza viruses are constantly changing, making it possible for them to infect people and easily spread.⁷
- Last three pandemics killed approximately 1.1 million (1957), 1 million (1968) and 0.2 - 0.6 million (2009) people.^{8, 9, 10}

Our Pipeline and Products

Products and Pipeline

BLB-750* Injectable, whole virion, cell culture-based pandemic influenza vaccine
TAK-019* Novavax [®] COVID-19 Vaccine [recombinant, adjuvanted]
TAK-003 Dengue Tetravalent Vaccine [live, attenuated]

Status


Approved in Japan to help protect against H5N1
Approved and launched in Japan to help protect against COVID-19
Approved and launched in markets around the world The Phase 3 trial is ongoing

Established Vaccines Portfolio in Japan

• Measles Rubella [^]
• Mumps
• Egg-based Seasonal Flu (Denka)
• Varicella [^] (Biken)
• Japanese Encephalitis (Biken)

Efficacy and safety of pipeline products are currently under investigation and there is no guarantee such products will be approved for the uses identified within. Regulatory approval of any of these products or uses is dependent on the completion of the study programs and review by relevant regulatory authorities.

Our Global Footprint



Takeda's Access to Medicines Strategy

More than two billion people around the world still do not have access to medicines, with low- and middle-income countries (LMICs) often facing the highest burden of disease. We're committed to broadening sustainable access to our innovative medicines in LMICs and in countries with evolving health care systems. We do this by working collaboratively to strengthen local health care systems and by addressing barriers to access at each stage of the patient journey.

References

1. World Health Organization. Vaccines and Immunization. Retrieved April 25, 2024.
2. GAVI. Cost-effective. February 2020. Retrieved April 25, 2024.
3. CDC. Global Immunization. April 20, 2023, Retrieved April 25, 2024.
4. World Health Organization. Dengue and Severe Dengue. World Health Organization. Published March 17, 2023.
5. World Health Organization. Coronavirus disease (COVID-19). October 2020. Retrieved April 25, 2024.
6. World Health Organization. WHO Coronavirus (COVID-19) Dashboard. Retrieved April 25, 2024.
7. Centers for Disease Control and Prevention. Past Pandemics. August 2018. Retrieved April 25, 2024.
8. Centers for Disease Control and Prevention. 1957-1958 Pandemic (H2N2 virus). January 2019. Retrieved April 25, 2024.
9. Centers for Disease Control and Prevention. 1968 Pandemic (H3N2 virus). January 2019. Retrieved April 25, 2024.
10. Centers for Disease Control and Prevention. 2009 H1N1 Pandemic (H1N1pdm09 virus). June 2019. Retrieved April 25, 2024.

Footnotes

* Japan only

^ Takeda has a measles-rubella combined vaccine, a measles vaccine and a rubella vaccine on the Japanese market.

Y Takeda's varicella vaccine has been approved for an additional indication treating herpes-zoster.